Agents that degrade the androgen receptor act by reducing the amount of androgen receptor protein in tumor cells. We believe that galeterone’s activity in CRPC patients whose tumor cells express AR-V7 is the result of its androgen receptor degradation mechanism. There are no currently marketed drugs whose mechanism of action entails degradation of the androgen receptor. Therefore, galeterone represents a potential first-in-class therapeutic opportunity.
In addition, under a license from the University of Maryland, Baltimore, Tokai has a drug discovery platform, known as ARDA (Androgen Receptor Degradation Agents), which enables us to identify and develop novel compounds designed to have potent androgen receptor degradation activity. Our most advanced compound from this platform is currently in preclinical development.